GLENMARK · Healthcare
Glenmark Pharmaceuticals Ltd. reported revenue of ₹3,264 cr for April to June 2025, +0.6% on the year and +0.2% on the quarter. Over the last four quarters revenue comes to ₹13,342 cr, +11.0% on the four before.
Operating profit (EBITDA) was ₹581 cr, a margin of 17.8%, −33 bps on the year and +57 bps on the quarter. Over the last 8 quarters the margin has ranged from −8.3% to 18.1%, averaging 13.9%. Operating costs grew +1.0%, broadly with revenue, so operating profit kept pace with sales.
Net profit was ₹47.0 cr, −86.2% on the year and +1,075.0% on the quarter, with earnings per share of ₹1.66. Profit before other income, one-offs and tax grew faster, at −8.8%; other income, one-offs or tax held the headline back. The tax rate was 51% against an average of 30% over the previous 4 quarters, which weighed on profit this quarter.
On earnings per share of ₹26.70 over the last four quarters, the stock at ₹2,225.30 trades at 83.3 times trailing earnings.
Written from the quarterly statements. The filing read adds the balance sheet and cash flow, the auditor's review, segment results, one-off items line by line and what management said on the call.
No check fired. That is a statement about the checks below, not a verdict on the company.
Could not run on this quarter: Exceptional items that recur, Cash behind the profit, Receivables against sales, Inventory against sales, Borrowing while holding cash, Auditor's review or audit report, IPO money used as stated, Related-party transactions, Exits, postponements, restatements, Promoter pledges and allotments, Earlier promises against delivery, When the results were filed. Most need the filing read (balance sheet, cash flow, auditor, disclosures).
Net profit a year ago, each driver's change, and net profit now. Blue added profit, red took it away.
| Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹3,207 cr | ₹2,507 cr | ₹3,063 cr | ₹3,244 cr | ₹3,434 cr | ₹3,388 cr | ₹3,256 cr | ₹3,264 cr | ₹6,047 cr | ₹3,901 cr | ₹3,771 cr | ₹4,018 cr |
| YoY | — | — | — | +7% | +7% | +35% | +6% | +1% | +76% | +15% | +16% | +23% |
| EBITDA margin | 14.4% | −8.3% | 16.5% | 18.1% | 17.5% | 17.7% | 17.2% | 17.8% | 39.0% | 22.3% | 20.2% | 20.0% |
| Other income, % of PBT | — | — | 63% | 7% | 8% | 7% | −4,513% | −309% | −122% | −26% | −47% | 10% |
| Exceptional items | — | — | — | — | — | — | — | — | — | — | — | — |
| Tax rate | — | — | — | 26% | 25% | 24% | 45% | 51% | 37% | 24% | 22% | 25% |
| Net profit | −₹62.0 cr | −₹331 cr | −₹1,214 cr | ₹340 cr | ₹354 cr | ₹348 cr | ₹4.0 cr | ₹47.0 cr | ₹610 cr | ₹403 cr | ₹301 cr | ₹483 cr |
| YoY | — | — | — | +97% | — | — | — | −86% | +72% | +16% | +7,425% | +928% |
| Core profit YoY | — | — | — | +136% | +118% | — | +81% | −9% | +396% | +59% | +55% | +47% |
| EPS | −₹2.90 | −₹12.45 | −₹43.17 | ₹12.06 | ₹12.55 | ₹12.33 | ₹0.16 | ₹1.66 | ₹21.63 | ₹14.29 | ₹10.68 | ₹17.11 |
| Flags | · | · | 1 | 1 | 1 | 1 | 1 | ✓ | ✓ | 1 | 2 | 1 |
Each quarter is read with the same rules. Balance-sheet and cash checks run on half-year and annual quarters; filing-read checks run where a read exists.
Glenmark Pharmaceuticals Ltd. reported revenue of ₹3,264 cr (+0.6% on the year) and net profit of ₹47.0 cr (−86.2% on the year) for April to June 2025.
Profit before other income, exceptional items and tax moved −8.8% on the year, against −86.2% for reported profit.
None of the 7 checks that could run raised a question.
No. FinMinutes reports what was filed and the questions the numbers raise. It does not recommend buying, selling or holding any security.
Numbers as filed with the exchanges, read by rules. Every flag is a question with its source, not an accusation. FinMinutes is a financial data and analytics platform; nothing here is a recommendation to buy, sell or hold any security. How each check works.